Why GeneDx Holdings Corp.’s (WGS) Stock Is Up 7.12%
As of Friday, August 07, GeneDx Holdings Corp.’s WGS share price has surged by 7.12%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. WGS
$87.07
4.52
5.47%
August 21, 2026 4:00:00 PM
EST
Volume: 555,209
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Commentary & Analysis
Which Is a Better Investment, NeoGenomics, Inc. or GeneDx Holdings Corp. Stock?
Learn more about whether NeoGenomics, Inc. or GeneDx Holdings Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why GeneDx Holdings Corp.’s (WGS) Stock Is Up 5.35%
As of Wednesday, July 29, GeneDx Holdings Corp.’s WGS share price has surged by 5.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why GeneDx Holdings Corp.’s (WGS) Stock Is Up 6.90%
As of Tuesday, July 28, GeneDx Holdings Corp.’s WGS share price has surged by 6.90%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why GeneDx Holdings Corp.’s (WGS) Stock Is Down 5.62%
As of Friday, July 10, GeneDx Holdings Corp.’s WGS share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | WGS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,461.9 | $1,982.5 | 56% |
|
| Shares Out (Mil) | 29.7 | 77.7 | 36% |
|
| Institutional Ownership | 98.0% | 86.1% | 77% |
|
| Float (Mil) | 19.1 | 52.1 | 28% |
|
| Beta | 1.97 | 0.75 | 92% |
|
| Avg Daily Volume (000s) | 603 | 637 | 61% |
|
| Price Change (52-week) |
(31.6%) | 79.7% | 22% |
|
| Growth | WGS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.0% | 10.9% | 80% |
|
| Net Income (5yr) | 38.6% | (1.6%) | 90% |
|
| EPS (5yr) | na | 0.3% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (17.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | $0.073 | $0.128 | $1.169 | |
| Month Ago EPS | $0.103 | ($0.064) | $1.104 | |
| # Rev Up | 2 | 1 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.115 | $0.110 | $1.231 | |
| Year/Year Chg | (112.2%) | (117.4%) | (350.3%) | |
| Financials | WGS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $454 | $1,504 | 40% |
|
| Net Income (TTM) (Mil) | ($106) | $28 | 11% |
|
| EPS (TTM) | ($3.640) | $0.200 | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($49) | $162 | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $9 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $162 | $338 | 48% |
|
| Enterprise Value (Q1) (Mil) | $2,334 | $2,416 | 51% |
|
| Valuation | WGS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.08 | 2.79 | 90% |
|
| P/E | na | 25.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | WGS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.4% | 27.8% | 80% |
|
| Net Margin | (23.4%) | 1.2% | 16% |
|
| ROA | (22.5%) | 2.2% | 19% |
|
| ROE | (40.8%) | 7.2% | 17% |
|
| Liabilities to Assets | 49.3% | 58.6% | 41% |
|
| F-Score | 4 | 5 | na |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.5% |
| +/- S&P 500: | +14.0 |
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.7% |
| +/- S&P 500: | +15.2 |
